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ABSTRACT
Immunosuppressants including corticosteroids (prednisolone >15 mg/day) are responsible for an increased risk of susceptibility to infections 
(especially pneumonia, tuberculosis [TB] including extra pulmonary TB), an important safety concern when providing immunosuppressive therapy. 
Anti-TB treatment (ATT) is medicines used to treat tuberculosis, an infectious disease which can affect lungs and other organs. Isoniazid, rifampicin, 
and pyrazinamide are known to cause ATT induced hepatitis. The prevalence of immunosuppressant induced TB and pyrazinamide induced 
hepatotoxicity during treatment for active TB ranges to about 0.6%-1% and <1%, respectively. Here, we illustrate a typical case report of a 61-year-old 
woman who is a known case of interstitial lung disease and developed TB arthritis following therapy with the long-term use of immunosuppressants 
(prednisolone, azathioprine, leflunomide, and sulfasalazine). ATT regimen was started for TB arthritis which was later modified along with addition of 
liver protectant due to the development of hepatotoxicity. The causality of both the adverse drug reactions was confirmed to be probable via NARANJO 
causality assessment scale. This case highlights the incidence of infectious complications like TB which may be expected to be encountered more 
frequently in the future due to the increasing use of immunosuppressants for the treatment of allergic and inflammatory disorders.
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INTRODUCTION
Immunosuppressive therapy (IMT) is considered the cornerstone of the 
treatment for gastrointestinal diseases and in the post-transplantation 
setting. Long-term use of these immunosuppressants [1] can 
compromise the immune system. The inflammation in interstitial lung 
disease (ILD) is being treated with steroids (e.g.,: Prednisolone) and 
other immunosuppressants conventionally (e.g.,: Azathioprine, mofetil 
or cytoxan) [2] which may increase the chance of developing severe and 
opportunistic infections (especially pneumonia and tuberculosis [TB] 
including extra pulmonary TB), osteoporosis (weakening of bones), 
etc., especially by the long-term use in combination with steroids 
(prednisolone >15 mg/day) [3-5]. The overall rate of steroid associated 
infectious complications was found to be 12.7% in those randomly 
allocated to corticosteroids compared with 8% in those receiving 
placebo in a meta-analysis of pooled data from controlled clinical 
trials which comprised 4198 patients with various diseases. Hospital 
mortality rate due to infections associated with IMT was found to be 
78% in another study. In a study of controlled trial with 100 patients 
having gastroenterological disorders, the odds ratio for opportunistic 
infections was found to be >4.4 when the treatment was combined 
with infliximab, corticosteroids, and azathioprine [6]. In addition, the 
prevalence of miliary TB in malignant disease is 3 times higher than 
in general population, and its mortality rate is about 25-30% in adults. 
Extra spinal TB osteomyelitis is rare and comprises about 2-3% of 
all cases of osteoarticular TB; with the hip and knee joints being the 
most common following spinal involvement [2]. TB affecting the ulna 
is uncommon but is found to be more common in diaphysis. As per 
the guidelines of the American Thoracic Society for TB, in patients 
undergoing long-term high doses of steroid therapy over a month 
must be considered for prophylactic anti-TB medication to counter 
the serious toxicity that steroids may induce. Patients diagnosed with 
TB are usually treated with first line anti-TB treatment (ATT), major 
side effects of which can cause significant morbidity and compromise 
treatment regimens for TB [7]. Here, we present a case which focusses 
on the important recognition of risk factors, monitoring for clinical 
course and laboratory results and patient education so as to curb 
the occurrence of untoward reactions which may thus result in a 
prescription cascade.
CASE REPORT
A 61-year-old female patient was referred from a local hospital with 
features of ILD. She was on Wysolone 20 mg OD since 5 years. On 
evaluation, RA factor was found to be positive and was added on 
hydroxychloroquine 200 mg OD, leflunomide (Lefno) 20 mg OD, and 
azathioprine (Azoran) 50 mg BD. She, however, started taking half 
tablet of 50 mg Azoran due to excessive tiredness and wrist joint pain; 
without any medical advice. The patient was presented with swelling 
in the right wrist joint after approximately 3 years of taking multiple 
immunosuppressants, which gradually increased in size since the past 
10 months with gradual waxing and waning. Swelling was associated 
with pain which was insidious in onset and gradually increasing with 
exacerbation since the past 5 months, with associated restriction of 
movements. As the swelling and pain in the wrist joint worsened, the 
patient was made to undergo a synovial biopsy, magnetic resonance 
imaging, and smear acid-fast bacilli from wrist joint which confirmed 
TB. The worsening swelling and pain in wrist joint stressed the need to 
start Rituximab, but the plan was put on hold owing to deterioration of 
TB. She was started on four drug ATT regimen following which her liver 
function tests (LFT) values increased three-fold higher than the normal 
level, resulting in hepatitis. Initially, ATT was stopped completely and 
sequentially added after serial monitoring of LFT. Due to deterioration 
of TB in wrist joint, immunosuppressants including leflunomide 
and azathioprine had to be stopped. As per clinicoradiological and 
functional response, steroid dose was tapered and stopped. Due to 
worsening liver enzymes, pyrazinamide 1250 mg OD was replaced with 
levofloxacin 750 mg OD and continued ATT as per standard guidelines. 
The patient was taken up for wound debridement and arthrodesis of 
the right wrist joint and was started on adequate analgesics (Ultracet 
BD which is a combination of tramadol 37.5 mg and acetaminophen 
325 mg) and given limb elevation. The supportive measures and 
appropriate treatment provided, thus, resulted in complete resolution 
of the patient’s symptoms.
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DISCUSSION
Table 1 shows the clinical profile of our patient including her 
demographic details, medical condition, the drugs prescribed 
(immunosuppressant and ATT medications), and the laboratory tests 
carried out to confirm TB and hepatitis.
Fig. 1 depicts the soft tissue lesion associated with fusion of carpal bone 
with the involvement of ulnar head with subchondral sclerosis and 
cystic changes.
Fig. 2 implies the increase in serum glutamate-pyruvate transaminase 
and serum glutamic oxaloacetic transaminase levels by about twice its 
normal levels with the inclusion of pyrazinamide in the ATT regimen.
This case shows a causality score of 8 for TB arthritis and 5 for hepatitis 
using NARANJO probability scale and causality of both the adverse drug 
reactions were found to be probable.
The prevalence of immunosuppressant induced TB and pyrazinamide 
induced hepatotoxicity during treatment for TB ranges to about 
0.6-1% and <1%, respectively, according to recent meta-analysis 
studies [8]. TB (mycobacterium tuberculosis) is a common infection 
associated to immunosuppressant therapy involving the treatment 
with corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, 
cyclosporine, and infliximab [9]. Isoniazid (INH) [10], rifampicin, 
and pyrazinamide are first-line ATT drugs which cause drug induced 
hepatotoxicity. Acetyl hydrazine, a metabolite of INH is responsible 
for liver damage. Rifampicin is stated to cause transient elevation in 
liver enzymes within first 8 weeks of therapy in 10-15% patients but 
causes hepatotoxicity in <1%. Pyrazinamide induced hepatotoxicity 
is dose-related and can occur at any time of therapy, also known to 
cause fulminant hepatitis. As per a recent review on current treatment 
modalities for TB, the individual therapeutic regimen for TB must be 
resolved in view of the current strategies available [11]. If possible 
immunosuppressant should be stopped or withheld or should be 
given in the lowest possible dose after assessing the patient’s clinical 
condition as per American College of Rheumatology guidelines [12]. 
Hepatotoxic drugs should be stopped if LFT increases three-fold higher 
than normal range and can be re-introduced sequentially in the order:
INH → Rifampicin → Pyrazinamide
CONCLUSION
This case highlights the incidence of infectious complications like TB 
which may be expected to be encountered more frequently in the future 
due to the increasing use of immunosuppressants for the treatment 
of allergic and inflammatory diseases. Patients on ATT should be 
given proper counseling before starting the therapy and, urged to 
report and consult physician/pharmacists on persisting symptoms if 
any. TB arthritis and hepatotoxicity can prolong the hospital stay or 
may result in readmission, thus contributing to increase in morbidity, 
mortality, and total cost for the hospitalized patient. The recognition of 
risk factors, monitoring for clinical course and laboratory results and 
patient education might be able to prevent such events.
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